These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 19835478)

  • 1. Transmission of drug-resistant HIV-1 is stabilizing in Europe.
    Vercauteren J; Wensing AM; van de Vijver DA; Albert J; Balotta C; Hamouda O; Kücherer C; Struck D; Schmit JC; Asjö B; Bruckova M; Camacho RJ; Clotet B; Coughlan S; Grossman Z; Horban A; Korn K; Kostrikis L; Nielsen C; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Riva C; Ruiz L; Salminen M; Schuurman R; Sonnerborg A; Stanekova D; Stanojevic M; Vandamme AM; Boucher CA
    J Infect Dis; 2009 Nov; 200(10):1503-8. PubMed ID: 19835478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes.
    SPREAD programme
    AIDS; 2008 Mar; 22(5):625-35. PubMed ID: 18317004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome.
    Jakobsen MR; Tolstrup M; Søgaard OS; Jørgensen LB; Gorry PR; Laursen A; Ostergaard L
    Clin Infect Dis; 2010 Feb; 50(4):566-73. PubMed ID: 20085464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.
    Bracciale L; Colafigli M; Zazzi M; Corsi P; Meraviglia P; Micheli V; Maserati R; Gianotti N; Penco G; Setti M; Di Giambenedetto S; Butini L; Vivarelli A; Trezzi M; De Luca A
    J Antimicrob Chemother; 2009 Sep; 64(3):607-15. PubMed ID: 19608581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey.
    Yerly S; von Wyl V; Ledergerber B; Böni J; Schüpbach J; Bürgisser P; Klimkait T; Rickenbach M; Kaiser L; Günthard HF; Perrin L;
    AIDS; 2007 Oct; 21(16):2223-9. PubMed ID: 18090050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and epidemiological characterization of HIV-1 infection networks involving transmitted drug resistance mutations in Northern Greece.
    Skoura L; Metallidis S; Buckton AJ; Mbisa JL; Pilalas D; Papadimitriou E; Papoutsi A; Haidich AB; Chrysanthidis T; Tsachouridou O; Antoniadou ZA; Kollaras P; Nikolaidis P; Malisiovas N
    J Antimicrob Chemother; 2011 Dec; 66(12):2831-7. PubMed ID: 21933785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain.
    de Mendoza C; Rodriguez C; Colomina J; Tuset C; Garcia F; Eiros JM; Corral A; Leiva P; Aguero J; Torre-Cisneros J; Pedreira J; Viciana I; del Romero J; Saez A; Ortiz de Lejarazu R; Soriano V;
    Clin Infect Dis; 2005 Nov; 41(9):1350-4. PubMed ID: 16206115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection.
    Yerly S; Junier T; Gayet-Ageron A; Amari EB; von Wyl V; Günthard HF; Hirschel B; Zdobnov E; Kaiser L;
    AIDS; 2009 Jul; 23(11):1415-23. PubMed ID: 19487906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004.
    Lohse N; Obel N; Kronborg G; Jørgensen LB; Pedersen C; Larsen CS; Kvinesdal B; Sørensen HT; Gerstoft J
    Antivir Ther; 2006; 11(5):591-600. PubMed ID: 16964827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009.
    Youmans E; Tripathi A; Albrecht H; Gibson JJ; Duffus WA
    South Med J; 2011 Feb; 104(2):95-101. PubMed ID: 21206421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of transmitted antiretroviral drug resistance in treatment-naïve patients and factors influencing first-line treatment regimen selection.
    Huang HY; Daar ES; Sax PE; Young B; Cook P; Benson P; Cohen C; Scribner A; Hu H
    HIV Med; 2008 May; 9(5):285-93. PubMed ID: 18400075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world.
    Frentz D; Boucher CA; van de Vijver DA
    AIDS Rev; 2012; 14(1):17-27. PubMed ID: 22297501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.
    Hofstra LM; Sauvageot N; Albert J; Alexiev I; Garcia F; Struck D; Van de Vijver DAMC; Åsjö B; Beshkov D; Coughlan S; Descamps D; Griskevicius A; Hamouda O; Horban A; Van Kasteren M; Kolupajeva T; Kostrikis LG; Liitsola K; Linka M; Mor O; Nielsen C; Otelea D; Paraskevis D; Paredes R; Poljak M; Puchhammer-Stöckl E; Sönnerborg A; Staneková D; Stanojevic M; Van Laethem K; Zazzi M; Zidovec Lepej S; Boucher CAB; Schmit JC; Wensing AMJ; ; Puchhammer-Stockl E; Sarcletti M; Schmied B; Geit M; Balluch G; Vandamme AM; Vercauteren J; Derdelinckx I; Sasse A; Bogaert M; Ceunen H; De Roo A; De Wit S; Echahidi F; Fransen K; Goffard JC; Goubau P; Goudeseune E; Yombi JC; Lacor P; Liesnard C; Moutschen M; Pierard D; Rens R; Schrooten Y; Vaira D; Vandekerckhove LPR; Van den Heuvel A; Van Der Gucht B; Van Ranst M; Van Wijngaerden E; Vandercam B; Vekemans M; Verhofstede C; Clumeck N; Van Laethem K; Beshkov D; Alexiev I; Lepej SZ; Begovac J; Kostrikis L; Demetriades I; Kousiappa I; Demetriou V; Hezka J; Linka M; Maly M; Machala L; Nielsen C; Jørgensen LB; Gerstoft J; Mathiesen L; Pedersen C; Nielsen H; Laursen A; Kvinesdal B; Liitsola K; Ristola M; Suni J; Sutinen J; Descamps D; Assoumou L; Castor G; Grude M; Flandre P; Storto A; Hamouda O; Kücherer C; Berg T; Braun P; Poggensee G; Däumer M; Eberle J; Heiken H; Kaiser R; Knechten H; Korn K; Müller H; Neifer S; Schmidt B; Walter H; Gunsenheimer-Bartmeyer B; Harrer T; Paraskevis D; Hatzakis A; Zavitsanou A; Vassilakis A; Lazanas M; Chini M; Lioni A; Sakka V; Kourkounti S; Paparizos V; Antoniadou A; Papadopoulos A; Poulakou G; Katsarolis I; Protopapas K; Chryssos G; Drimis S; Gargalianos P; Xylomenos G; Lourida G; Psichogiou M; Daikos GL; Sipsas NV; Kontos A; Gamaletsou MN; Koratzanis G; Sambatakou H; Mariolis H; Skoutelis A; Papastamopoulos V; Georgiou O; Panagopoulos P; Maltezos E; Coughlan S; De Gascun C; Byrne C; Duffy M; Bergin C; Reidy D; Farrell G; Lambert J; O'Connor E; Rochford A; Low J; Coakely P; O'Dea S; Hall W; Mor O; Levi I; Chemtob D; Grossman Z; Zazzi M; de Luca A; Balotta C; Riva C; Mussini C; Caramma I; Capetti A; Colombo MC; Rossi C; Prati F; Tramuto F; Vitale F; Ciccozzi M; Angarano G; Rezza G; Kolupajeva T; Vasins O; Griskevicius A; Lipnickiene V; Schmit JC; Struck D; Sauvageot N; Hemmer R; Arendt V; Michaux C; Staub T; Sequin-Devaux C; Wensing AMJ; Boucher CAB; van de Vijver DAMC; van Kessel A; van Bentum PHM; Brinkman K; Connell BJ; van der Ende ME; Hoepelman IM; van Kasteren M; Kuipers M; Langebeek N; Richter C; Santegoets RMWJ; Schrijnders-Gudde L; Schuurman R; van de Ven BJM; Åsjö B; Kran AB; Ormaasen V; Aavitsland P; Horban A; Stanczak JJ; Stanczak GP; Firlag-Burkacka E; Wiercinska-Drapalo A; Jablonowska E; Maolepsza E; Leszczyszyn-Pynka M; Szata W; Camacho R; Palma C; Borges F; Paixão T; Duque V; Araújo F; Otelea D; Paraschiv S; Tudor AM; Cernat R; Chiriac C; Dumitrescu F; Prisecariu LJ; Stanojevic M; Jevtovic D; Salemovic D; Stanekova D; Habekova M; Chabadová Z; Drobkova T; Bukovinova P; Shunnar A; Truska P; Poljak M; Lunar M; Babic D; Tomazic J; Vidmar L; Vovko T; Karner P; Garcia F; Paredes R; Monge S; Moreno S; Del Amo J; Asensi V; Sirvent JL; de Mendoza C; Delgado R; Gutiérrez F; Berenguer J; Garcia-Bujalance S; Stella N; de Los Santos I; Blanco JR; Dalmau D; Rivero M; Segura F; Elías MJP; Alvarez M; Chueca N; Rodríguez-Martín C; Vidal C; Palomares JC; Viciana I; Viciana P; Cordoba J; Aguilera A; Domingo P; Galindo MJ; Miralles C; Del Pozo MA; Ribera E; Iribarren JA; Ruiz L; de la Torre J; Vidal F; Clotet B; Albert J; Heidarian A; Aperia-Peipke K; Axelsson M; Mild M; Karlsson A; Sönnerborg A; Thalme A; Navér L; Bratt G; Karlsson A; Blaxhult A; Gisslén M; Svennerholm B; Bergbrant I; Björkman P; Säll C; Mellgren Å; Lindholm A; Kuylenstierna N; Montelius R; Azimi F; Johansson B; Carlsson M; Johansson E; Ljungberg B; Ekvall H; Strand A; Mäkitalo S; Öberg S; Holmblad P; Höfer M; Holmberg H; Josefson P; Ryding U
    Clin Infect Dis; 2016 Mar; 62(5):655-663. PubMed ID: 26620652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmitted drug-resistance in human immunodeficiency virus-infected adult population in El Salvador, Central America.
    Holguín Á; Yebra G; Martín L; de Pineda AT; Ruiz LE; Quezada AY; Nieto AI; Escobar G
    Clin Microbiol Infect; 2013 Dec; 19(12):E523-32. PubMed ID: 23782115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of drug-resistant HIV type 1 at the time of initiation of antiretroviral therapy in Portland, Oregon.
    MacVeigh MS; Kosmetatos MK; McDonald JE; Reeder JL; Parrish DA; Young TP
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):337-42. PubMed ID: 22697610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection.
    Booth CL; Garcia-Diaz AM; Youle MS; Johnson MA; Phillips A; Geretti AM
    J Antimicrob Chemother; 2007 Mar; 59(3):517-24. PubMed ID: 17213262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.